PTEN and cancer: Previously, we and others have shown that k-Ras mutant [5, 34], PTEN-deleted [5], Met [5], and Myc [11] overexpressing cancer cells are more sensitive to Ran knockdown compared to their wild-type counterparts, suggesting that Ran may be a potential therapeutic target for cancers with these oncogenic mutations.